The tumor targeting portion of HPK is derived from the binding ligand for HER3, specifically comprising the receptor binding portion of heregulin (or neuregulin) 1-⍺1; it also induces rapid receptor-mediated endocytosis (Figure 3a) [18,23]. Here, NRG1 is linked to neoplasm.